Navigation Links
sanofi-aventis: Strong Performance of Growth Platforms in Q1 2011
Date:4/28/2011

age number of shares outstanding of 1,305.2 million in the first quarter of 2011 and 1,307.3 in the  first quarter of 2010.Appendix 9: Definitions Re-presentation of Merial resultsIn accordance with IFRS 5.36 and as Merial has ceased to be qualified as held for sale or exchange in Q1/2011, the results of Merial classified as held for sale or exchange in previously-issued financial statements have been reclassified and included in income from continuing operations for all periods presented.

Definitions of non-GAAP financial indicatorsNet sales at constant exchange rates

When we refer to changes in our net sales "at constant exchange rates," this means that we exclude the effect of changes in exchange rates.

We eliminate the effect of exchange rates by recalculating net sales for the relevant period at the exchange rates used for the previous period.

Reconciliation of reported net sales to net sales at constant exchange rates for the first quarter of 2011(millions of euros)Q1 2011Net sales

7,779Effect of exchange rates

(289)Net sales at constant exchange rates

7,490Net sales on a constant structure basis

We eliminate the effect of changes in structure by restating prior-period net sales as follows:

  • by including sales from the acquired entity or product rights for a portion of the prior period equal to the portion of the current period during which we owned them, based on sales information we receive from the party from whom we make the acquisition;
  • similarly, by excluding sales in the relevant portion of the prior period when we have sold an entity or rights to a product;
  • for a change in consolidation method, by recalculating the prior period on the basis of the method used for the current period.

  • Worldwide presence of Plavix®/Iscover®, Avapro®/Aprovel®

    When we refer to the "worldwide presence" of a product, we mean our consolida
    '/>"/>

    SOURCE sanofi-aventis
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

    Related medicine technology :

    1. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
    2. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
    3. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
    4. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
    5. AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study
    6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
    7. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
    8. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
    9. US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
    10. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
    11. Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of Mr. C Causes Major Interest in the Scientific Community
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
    (Date:1/14/2014)... 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company ... Progressive Home Medical Equipment, Inc. ("Progressive") of Clarion, ... the acquisition were not disclosed. Progressive is ... wide range of sleep, mobility, and respiratory products to customers ...
    (Date:1/14/2014)...   Oligomerix, Inc. , a privately held company pioneering ... (AD) and related neurodegenerative disorders, announced today the relocation ... as of January 15, 2014 and expanded ... Medical College. Oligomerix, which is focused on ...
    Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
    ... Inc. (OTCBB: ECTE), a company developing its needle-free ... continuous glucose monitoring system and its Prelude™ SkinPrep ... Patrick T. Mooney, M.D., CEO, President and Chairman ... at the Jefferies 2011 Global Healthcare Conference. ...
    ... CHENGDU, China, June 3, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical ... pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized ... announced that the Board of Directors has reinstated the ... to 3 million TPI,s common stock on the open ...
    Cached Medicine Technology:TPI Board Reinstates Stock Repurchase Program 2
    (Date:4/17/2014)... cause of neuronal death in Parkinson,s disease is still ... be mistaken for foreign invaders and killed by the ... diseases like type I diabetes, celiac disease, and multiple ... April 16, 2014, in Nature Communications . , ... Parkinson,s disease; but if true, it could lead to ...
    (Date:4/17/2014)... team led by researchers at UC Davis has shown ... key role in cell division, also boosts the mitochondrial ... time the complex has been shown to perform both ... excellent target to control cellular energy production, potentially advancing ... online today in the journal Developmental Cell . ...
    (Date:4/17/2014)... April 17, 2014 Meaningful long-term survival ... cancer of the abdomen when treated with cytoreductive ... to a first-of-its-size analysis by physicians at Wake ... has the largest reported, single-center experience with cytoreductive ... Levine, M.D., and analysis of 20 years, worth ...
    (Date:4/17/2014)... 2014 Giving patients adrenaline after they suffer a cardiac ... prospects of surviving long-term, according to new research conducted ... patients who have a cardiac arrest get adrenaline, which ... for decades," said Dr. Steve Lin, an emergency physician ... advances in medical treatment, long-term survival rates of patients ...
    (Date:4/16/2014)... The Translational Genomics Research Institute (TGen) recently honored two ... their support of TGen,s research into brain, colon and ... Scottsdale. , Catherine Ivy, Founder and President of The ... McCain Leadership Award, named for U.S. Sen. John McCain ...
    Breaking Medicine News(10 mins):Health News:Is Parkinson's an autoimmune disease? 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
    ... Drug Information Association (DIA), in collaboration with FDA, the Medical ... Radiopharmaceuticals (CORAR), PhRMA, and the American Medical Informatics Association (AMIA), ... Uses of Medical Imaging in the Development of New Biopharmaceutical ... ...
    ... is a break-through Nitinol wire product which features an exclusive ... acid solutions which cause embrittlement. The resulting NitiBrite™ ... other known methods. , ... West ...
    ... Komen for the Cure(R), the,leader of the global ... G. Komen for the Cure Advocacy Alliance, have ... self awareness and the need for,increased access to ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070122/NYM084LOGO ), Komen for the ...
    ... Companies Will Discuss Recent FDA Advisory Regarding Byetta, ... LLY ) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... 2008 at 5:00 p.m. EDT to discuss the,recent FDA ... Lilly will be Donald Therasse, M.D., vice president of ...
    ... fail to alert docs to effectiveness of alternative therapies ... slowed the use of antipsychotic drugs in seniors with ... the elderly increased, a finding which suggests that warnings ... say. , Between late 2002 and June 2005, ...
    ... HCA marked its 40th,anniversary during a special program for ... featured HCA Co-Founder and Chairman Emeritus, Dr. Thomas,Frist, Jr. ... who spoke about,HCA,s founding, mission and tradition of caring ... of Caring" program was a,prelude to HCA,s annual Caring ...
    Cached Medicine News:Health News:Shaping Best Practices For Standardized Medical Imaging In Clinical Trials 2Health News:Shaping Best Practices For Standardized Medical Imaging In Clinical Trials 3Health News:NitiBrite™ - Break-through in Nitinol Wire Product for Medical Devices 2Health News:Komen Travels to Democratic Convention in Denver to Raise Awareness of Breast Cancer Issues 2Health News:Lilly and Amylin Set Date and Time for Conference Call 2Health News:Antipsychotic Drug Use Up in Elderly Despite Warnings 2Health News:HCA Celebrates 40th Anniversary 2
    ... To Manually Dilate A Small Pupil With ... Maximizes Safety By Allowing The Iris Hooks ... To The Plane Of The Anterior Capsule, ... Tears. Pupil Stretching Is Also Maximized, With ...
    ... To Rest Either Nasally Or Temporally ... Allowing Eyelids To Be Opened From ... Possible Aperture., ,Open And Close With ... To The Globe During Clear Corneal ...
    ... Designed To Rest Either Nasally Or ... Over, Allowing Eyelids To Be Opened ... Widest Possible Aperture.,Open And Close With ... To The Globe During Clear Corneal ...
    ... Special Low-profile Hourglass Jaw Design Holds ... A Minimal Incision.,Mirror Polished Blades Keep ... Handle Mechanism Offers Control Over Release ... The Lens From Tilting During Insertion.,Reusable, ...
    Medicine Products: